Lupus Erythematosus, Systemic
Conditions
Brief summary
The trial will evaluate pharmacodynamics，pharmacokinetics，safety，and efficacy of JMKX000189 versus placebo in participants with moderately to severely active systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment.
Interventions
DRUGJMKX000189
JMKX000189 will be administered orally once a day
DRUGPlacebo
Placebo will be administered orally once a day
Sponsors
Jemincare
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects must have been diagnosed with systemic lupus erythematosus at least 24 weeks prior to screening and must be assessed to meet 2019 EULAR/ACR SLE classification criteria during screening. 2. the subject must meet one of the following at screening: a. ANA titer ≥1:80;b. anti-dsDNA antibody positive; c. Anti-Smith antibody positive. 3. At least one of the following SLE background standard therapies (including no more than one immunosuppressant) was required for 12 weeks prior to randomization, and the dose must remain stable at least 30 days until randomization and throughout study participation.
Exclusion criteria
1. Active lupus nephritis (defined as urinary protein \>1g/24 h or urinary total protein/creatinine ratio (UPCR) \>1 mg/mg (113 mg/mmol) within 8 weeks prior to screening or at randomization). 2. Active lupus of the central nervous system (CNS) (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, or CNS vasculitis) within 60 days prior to randomization. 3. Myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, grade III/IV heart failure, or untreated severe sleep apnea occurred ≤6 months before screening. 4. Previous or current atrioventricular block of degree Ⅱ or Ⅲ, sick sinus syndrome, symptomatic bradycardia, atrial flutter or atrial fibrillation, ventricular arrhythmia or syncope associated with heart disease, or other arrhythmia deemed clinically significant and requiring intervention or treatment. 5. A history of severe respiratory disease or interstitial pneumonia or pulmonary fibrosis，which were found by the medical history or lung function test or chest CT examination conducted during screening or within 3 months prior to screening;Or abnormal pulmonary function of medical significance: 1 second forced expiratory volume (FEV1) or forced vital capacity (FVC)\<70% of the expected value, or FEV1 /FVC \< 0.7. 6. Patients with significant abnormalities in liver, renal function and blood routine during screening, including glutamate aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding 2 times the upper limit of normal value;Serum creatinine greater than 1.5 times the upper limit of normal;Hemoglobin \<90g/L;White blood cell count \<2.5×109/L, platelet count (PLT) \<75×109/L;Lymphocyte count \<0.8×109/L;Abnormal results of other laboratory tests may affect the completion of the test or interfere with the test results according to the investigator. 7. Use of cyclosporine, tacrolimus, pimelimus, and sirolimus within 1 month prior to randomization. 8. Use of thalidomide or lenalidomide within 2 months prior to randomization. 9. Rituximab, telitacicept, or leflunomide were used in the 6 months prior to randomization. 10. Use of Belliumab within 3 months prior to randomization. 11. Intravenous treatment with cyclophosphamide was received within 6 months prior to randomization or oral treatment with cyclophosphamide within 30 days prior to initial administration. 12. History of type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus with HbA1c\> 8%, or diabetic subjects with organ involvement (e.g. retinopathy or kidney disease).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Total Lymphocyte Count From Baseline to Week 12 | Baseline,Week 12 |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline to Week 4,8,12 and 16 in the modified SLEDAI (mSLEDAI) score | Baseline, Week 4, 8,12, and 16 |
| Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index-4 (SRI-4) Response at Week 4,8,12 and 16 | Baseline, Week 4, 8,12, and 16 |
| Percentage of Participants Achieving No worsening in Physician Global Assessment (PGA) of Disease Activity at Week 4,8,12 and 16, No worsening defined as an increase of PGA < 0.3 Points from baseline | Baseline, Week 4, 8,12, and 16 |
Countries
China
Contacts
Primary ContactQuanquan Yan
Backup ContactYahui Li
Outcome results
None listed